CCR2 and neoplasm: Treatment with poly A:U significantly increased the percentage of M0, M2-like, and Ly6C+CCR2+MHCIIneg cells expressing PD-L1 (Figure 5B), supporting the hypothesis that combining poly A:U with anti PD1/PDL1 inhibitors could potentiate anti-tumor immunity.